Convalescent plasma and hyperimmune globulin therapy in COVID-19. (3rd April 2021)

• Record Type: Journal Article
• Authors: Cagdas, Deniz
• Is Part Of: Expert review of clinical immunology. Volume 17:Number 4(2021)
• Page Start: 309
• Page End: 316
• Publication Date: 2021-04-03
• Subjects: Convalescent Plasma -- hyperimmune globulin -- efficacy -- adverse effects -- application -- use -- SARS-CoV-2 -- COVID-19 -- antibody -- autoantibody; Clinical immunology -- Periodicals; 616.079
• DOI: 10.1080/1744666X.2021.1894927
• Languages: English
• ISSNs: 1744-666X

Abstract

ABSTRACT: Introduction : Severe acute respiratory syndrome causing coronavirus SARS-CoV-2 (coronavirus disease 2019 (COVID-19)) has recently resulted in the recent global pandemic. As convalescent plasma (CP) therapy has been used with success in several viral infections before, it has become a treatment of choice. Medical literature is reviewed for randomized controlled studies using convalescent plasma therapy. Areas covered : More than one type of neutralizing antibody against a specific microorganism may be found in both CP and hyperimmune globulins. To give a standard titer of a specific neutralizing antibody to a patient, a reliable antibody titration assay should be developed. It is challenging to test the efficacy of the CP and HIG therapies with double-blind studies. There is a difficulty in the standardization of the CP and HIG study groups, as patients use various additional therapies. Different amounts and titers of CP and HIG and different titers of CP are used in patients. This review discusses the current knowledge on CP and HIG therapies used in COVID-19 disease. Expert opinion : The immune response to COVID-19 have diverse characteristics. The antibody produced after COVID-19 disease and vaccination is short-lived. Thus, CP should be an alternative especially in patients with lymphopenia and primary/secondary antibody deficiency.